Advertisement

Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start - Episode 6

Treatment Resistance in HIV

Published on: 
, , ,

Paul E. Sax, MD, and Sorana Segal-Maurer, MD, discuss treatment resistance in HIV and how it has changed over the years.

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following question:

  1. When we are talking about treatment resistance in HIV, what do we mean?
  2. Impact of drug resistance on the disease course
  3. Impact on the achievement of global targets
    • Most common mutations
  4. How has resistance in HIV treatment changed over the years?
  5. FDA approvals have provided options for those with resistance.

Advertisement
Advertisement